{{medical}}
{{Drugbox
| verifiedrevid = 462252883
| IUPAC_name = 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)<br>ethylamino]-anthracene-9,10-dione
| image = Mitoxantrone skeletal.svg

<!--Clinical data-->
| tradename = Novantrone
| Drugs.com = {{drugs.com|monograph|mitoxantrone-hydrochloride}}
| MedlinePlus = a608019
| pregnancy_US = D
| legal_status = Rx-only
| routes_of_administration = 主要为[[静脉注射|静脉注射]]

<!--Pharmacokinetic data-->
| bioavailability = n/a
| protein_bound = 78%
| metabolism = [[肝脏|肝脏]]（[[CYP2E1|CYP2E1]]）
| elimination_half-life = 75小时
| excretion = [[肾脏|肾脏]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 65271-80-9
| ATC_prefix = L01
| ATC_suffix = DB07
| PubChem = 4212
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01204
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4067
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = BZ114NVM5P
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08224
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50729
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 58

<!--Chemical data-->
| C=22 | H=28 | N=4 | O=6 
| molecular_weight = 444.481 [[克|g]]/[[摩尔_(单位)|mol]]
| smiles = O=C2c1c(c(NCCNCCO)ccc1NCCNCCO)C(=O)c3c2c(O)ccc3O
| InChI = 1/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
| InChIKey = KKZJGLLVHKMTCM-UHFFFAOYAS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KKZJGLLVHKMTCM-UHFFFAOYSA-N
}}

'''米托蒽醌'''（{{lang-en|'''Mitoxantrone'''}}）是一种[[蒽醌|蒽醌]]类（与[[蒽环类药物|蒽环类药物]]类似但不同）[[化疗|化疗]]药物。

==用途==
米托蒽醌被用于治疗多种[[癌症|癌症]]，其中主要包括[[远端转移|远端转移]]的[[乳癌|乳癌]]、[[急性淋巴细胞白血病|急性淋巴细胞白血病]]和[[非霍奇金氏淋巴瘤|非霍奇金氏淋巴瘤]]。<ref name="gale">{{Cite book|last=Thackery |first=Ellen |title=The Gale Encyclopedia of Cancer: L-Z |publisher=Thomson Gale |location=Detroit |year=2002 |page=708-710 |isbn=0-7876-5611-9}}</ref> 它与[[泼尼松|泼尼松]]被合用于[[远端转移|远端转移]]的[[激素|激素]]不敏感性[[前列腺癌|前列腺癌]]的二线治疗。这种联合疗法曾是一线治疗方法，直至最近被效果更好、患者生存期更长的[[多西他赛|多西他赛]]/泼尼松联合疗法取代。<ref>{{cite book |chapter=Cancer Chemotherapy |author=Katzung, Bertram G. |title=Basic and clinical pharmacology |publisher=McGraw-Hill Medical Publishing Division |location=New York |year=2006 |isbn=0-07-145153-6 |edition=10th |oclc=157011367}}</ref> 有研究显示它能够增加[[急性粒细胞白血病|急性粒细胞白血病]]第一次复发的儿童患者的生存率。<ref name="Parker">{{cite journal |author=Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V |title=Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial |journal=Lancet |volume= 376|issue= 9757|pages= 2009–2017|year=2010 |pmid=21131038 |doi=10.1016/S0140-6736(10)62002-8 |pmc=3010035}}</ref>

米托蒽醌还被用于治疗[[多发性硬化症|多发性硬化症]]，尤其是继发进展型。它并不能够治愈多发性硬化症，但能够有效减缓疾病的进展并延长复发缓解型和进展复发型的复发之间的间隔时间。<ref name="Fox">{{cite journal |author=Fox E |title=Management of worsening multiple sclerosis with mitoxantrone: a review |journal=Clin Ther |volume=28 |issue=4 |pages=461–74 |year=2006 |pmid=16750460 |doi=10.1016/j.clinthera.2006.04.013}}</ref>


==藥物設計理念==
[[File:Mitoxantrone_structure.svg|thumb]]

==作用机理==
米托蒽醌是一种[[拓扑异构酶II|拓扑异构酶II]][[拓扑异构酶抑制剂|抑制剂]]，通过抑制[[拓扑异构酶|拓扑异构酶]]来干扰癌细胞[[DNA复制|DNA复制]]、[[转录|转录]]与[[DNA修复|修复]]。

它还能[[嵌入_(化學)|嵌入]][[DNA|DNA]]双链的[[碱基|碱基]]之间，从而阻碍肿瘤[[细胞分裂|细胞分裂]]。<ref name="pmid">{{cite journal |author=Mazerski J, Martelli S, Borowski E |title=The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations |journal=Acta Biochim. Pol. |volume=45 |issue=1 |pages=1–11 |year=1998 |pmid= 9701490|doi= |url=}}</ref>

在多发性硬化症的治疗中米托蒽醌则是起到了[[免疫抑制剂|免疫抑制剂]]的作用。<ref name="mec" >{{Cite journal | doi = 10.1212/WNL.63.12_suppl_6.S15 | last1 = Fox | first1 = E. J. | title = Mechanism of action of mitoxantrone | journal = Neurology | volume = 63 | issue = 12 Suppl 6 | pages = S15–S18 | year = 2004 | pmid = 15623664 }}</ref>[[File:Mitoxantrone_mechanism.svg|thumb]]

==副作用==
与蒽环类药物一样，米托蒽醌的常见不良反应包括不同程度的[[恶心|恶心]]、[[呕吐|呕吐]]、[[脱发|脱发]]、[[骨髓抑制|骨髓抑制]]、心脏毒性等，其中骨髓抑制和心脏毒性为延迟性作用。最严重的副作用是不可逆的心肌病，并可能引起[[心力衰竭|心力衰竭]]；因此用药时必须定期进行[[心电图|心电图]]检查。<ref name="gale" /> 由于心脏毒性的缘故，米托蒽醌有着由身体表面积决定的终生剂量限制。<ref name="Fox"/>

==合成==
米托蒽醌可以由[[醌茜|醌茜]]（1,4-二羟基蒽醌）合成：<ref>{{Cite journal|doi=10.1021/jm00195a002|title=Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones|pmid=490545|year=1979|last1=Murdock|first1=K. C.|last2=Child|first2=R. G.|last3=Fabio|first3=P. F.|last4=Angier|first4=Robert D.|last5=Wallace|first5=Roslyn E.|last6=Durr|first6=Frederick E.|last7=Citarella|first7=R. V.|journal=Journal of Medicinal Chemistry|volume=22|issue=9|pages=1024}}</ref><br/>
[[File:Mitoxantrone_syn.svg|801px]]

==另见==
*[[匹杉琼|匹杉琼]]，一种正在研究中的类似药物

==参考资料==
{{Reflist}}

{{化疗药物}}

[[Category:拓扑异构酶抑制剂|Category:拓扑异构酶抑制剂]]
[[Category:IARC第2B类致癌物质|Category:IARC第2B类致癌物质]]
[[Category:醇|Category:醇]]
[[Category:酚|Category:酚]]
[[Category:蒽醌|Category:蒽醌]]